Jermonica Boardley is President and CEO of SIVAD Diagnostic Medical Group LLC ( https://sivadppe.com/ ), a minority-owned company dedicated to addressing the unique needs of underserved and unserved communities in the United States and globally, which most recently announced the launch of HarmGuard FX ( https://www.harmstopper.com/ ), a single, low-cost strip that provides an affordable, reliable way for people to test substances for fentanyl and xylazine (popularly known as tranq), two dangerous adulterants that are exacerbating the already critical opioid epidemic. Ms. Boardley is a graduate of Delaware State University, brings over 20 years of diverse corporate leadership experience to her role as President and CEO and her expertise spans Accounting, Finance, Human Resources, Communications, and Diversity, Equity & Inclusion (DE&I). Joseph Scrocco, is President & CEO, Diagnostic Solutions Group ( https://www.diagnosticsolutionsgroup.com/ ), the developer of HarmGuardFX, and their company has developed custom diagnostic solutions for over 25 years ranging from complex mass screening for blood banks to individual point-of-care testing with a focus on large-scale, global diagnostic needs, including antibody, molecular, and antigen tests in traditional and non-traditional settings. Their clients include Johnson & Johnson; Pfizer; Novo Nordisk; Abbott Labs; Ortho Clinical Diagnostics; the Red Cross; the governments of Nigeria, Ivory Coast, Bangladesh, Liberia, Jamaica, India, Mali; numerous Broadway companies; plus, hundreds of hospitals, urgent care centers, and long-term care facilities. Mr. Scrocco has a MS in Neurophysiology from University of Medicine and Dentistry of New Jersey, and an MA in Information Systems from New York University. ... https://www.youtube.com/watch?v=WU3xL4BQ1U0

ENA Respiratory ( https://enarespiratory.com/ ) is a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, including the elderly, those with chronic lung conditions and individuals with occupational risk (e.g. first responders, military or essential services personnel). The company is also developing its innate immune modulators as vaccine adjuvants. ENA Respiratory is based in Melbourne and Sydney, Australia Dr. Ruth Tal-Singer, Ph.D., Medicine Development Leader, ENA Respiratory, is an internationally recognized healthcare leader and clinical scientist with extensive Research and Development experience including recent roles as Vice President of Respiratory Medical Innovation R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals where during her career she led many projects that resulted in new insights, bringing new treatments to the market. She also formerly served as Chief scientific officer and CEO of the COPD Foundation, where she led the patient-centered research, education, and global community outreach advocacy organization focused on the prevention and early diagnosis and treatment of chronic lung diseases. Her vision led to the creation of World Bronchiectasis Day, observed on July 1. Dr. Tal-Singer’s idea resulted in global awareness of the under-researched and under-represented bronchiectasis disease in partnership with 20 other global patient advocacy, academic, and research organizations. As the leader of COPD360Net, the COPD Foundation’s digital health, medical devices, and therapeutics development accelerator network, she championed the partnership between ENA Respiratory and the COPD Foundation and served as a member of its Board of Directors on behalf of the COPD Foundation until March 31, 2023. Dr. Tal-Singer has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. She is adept at building and maintaining partnerships between Pharma, patients, academia and governments and has wide-ranging technical and scientific knowledge comprising molecular biology, immunology, application of digital technology and in vivo disease models (pre-clinical and clinical). She also led the initial clinical development of GSK’s inhaled anti-muscarinic portfolio, currently available to patients as Umeclidinium bromide. As a researcher, Dr. Tal-Singer has authored 180+ peer-reviewed papers including highly cited scientific publications. She has a Doctor of Philosophy (PhD), Molecular Biology / Microbiology, from University of Pennsylvania, did post-doctoral work at the Wistar Institute, and continues to lecture at the Institute of Translational Medicine and Therapeutics at Penn. Dr. Scott M. White, M.D., Chief Medical Officer, ENA Respiratory, is an infectious diseases physician who has spent over 17 years working in the pharmaceutical and biotech industry. Most recently he served as Vice President Clinical Development for the infectious diseases therapeutic area of Inovio Pharmaceuticals where he was responsible for the clinical development of immunotherapeutic and prophylactic DNA-based vaccines. Prior to this he was a Physician Project Leader for GlaxoSmithKline. In this role he was accountable for several development programs spanning pre-candidate selection through early stage clinical development of assets in the therapeutic areas of infectious diseases, hematology, and dermatology. During this time at GlaxoSmithKline, in collaboration with AstraZeneca, the EU Innovative Medicines Initiative, and medical and scientific leaders throughout Europe, he led the establishment of COMBACTE; a European antibacterial clinical trial network supporting the development of antibiotics targeting resistant organisms. Dr. White is also currently an independent consultant applying his experience and expertise in infectious diseases, immunology, molecular biology, and clinical development to support biotech and small pharma companies with progressing assets into early phase clinical development. Dr. White has his M.D. from Pennsylvania State University College, and did an Infectious Diseases Fellowship at University of Pittsburgh School of Medicine. ... https://www.youtube.com/watch?v=sMYKJSF8kYM

Sonia Arrison (https://soniaarrison.com/) is a best-selling author, analyst, entrepreneur, and investor. Sonia is founder of 100 Plus Capital (https://100pluscap.com/ - Investing in companies positively impacting human longevity), Chair of the Alliance for Longevity Initiatives (https://a4li.org/ - The first and only 501(c)(4) nonprofit organization founded with the goal of creating social and political action around the issues of combating age-related chronic conditions and increasing our number of healthy, disease-free years), co-founder of Unsugarcoat Media (acquired by Medium), and was an associate founder of Singularity University. Sonia’s research focuses on exponentially growing technologies and their impact on society. Her book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity, and gained national best-seller status. In addition to the Alliance for Longevity Initiatives, Sonia is a Board Member at the Thiel Foundation, Foresight Institute, and Woodland School. She is also a Senior Fellow at the Fraser Institute in Vancouver, British Columbia, and author of two previous books (Western Visions and Digital Dialog). Sonia was previously a Director and Senior Fellow in Tech Studies at the Pacific Research Institute, a columnist at TechNewsWorld, and hosted a radio show called “digital dialogue” on the Voice America network. ... https://www.youtube.com/watch?v=nl014JeeziI

Brigadier General (Res.) Uri Oron is Israeli Space Agency (ISA) Director ( https://www.space.gov.il/en ). ISA is a national agency operating under the auspices of the Ministry of Innovation, Science and Technology ( https://www.gov.il/he/departments/ministry_of_science_and_technology/govil-landing-page ), and they are responsible for initiating, leading and coordinating all activities of the civilian space program in Israel. Director Oron earned a bachelor’s from Auburn University at Montgomery, a Master degree with distinction from Haifa University, in National Security Policy Studies, and he is a graduate of USAF Air Command and Staff College at the US Air University and the Israel's National Security College. Director Oron served as a fighter pilot with command and operational experience of over thirty-two years in the Israel Air Force, having served in various positions, including squadrons wing commander and the head of the Israel Air Force’s Intelligence Directorate. Prior to joining the Israeli Space Agency, Director Oron managed operations in an Israeli Artificial Intelligence start-up and he has accumulated extensive experience in managing complex systems and implementing state-of-the-art technologies, based on broad-scale strategies. He has led innovative projects in the space field in collaboration with the IDF, as well as the defense industries, while also interfacing with the political echelon. ... https://www.youtube.com/watch?v=foJCzZvr0eE